| Name | Bivalirudin Acetate |
| Molecular Formula | C98H138N24O33 |
| CAS | 128270-60-0 |
| Sequence | D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH |
| Molecular Weight | 2180.33 |
| Purity (HPLC) | 99%min |
| Appearance | White powder |
| Single Impurity(HPLC) | 1%max |
| Amino Acid Composition | ±10% of theoretical |
| Peptide Content(N%) | ≥80.0% |
| Water Content(KF) | ≤8.0% |
| Acetate Content(HPLC) | ≤12% |
| MS(ESI) | Consistent |
| Mass Balance | 95.0~105.0% |
Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.
